Abstract
Anti-citrullinated protein antibodies (ACPA) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the recent disease classification criteria. However, there is a strong need for reliable markers for measuring and predicting joint damage and disease activity. Recently, antibodies directed against carbamylated antigens (anti-CarP antibodies) were identified. A total of 120 RA patients were tested for anti-CCP antibodies using different methods and for anti-CarP antibodies using carbamylated fetal calf serum according to the method described by Shi et al. Additionally, ACPA fine specificities (to three citrullinated peptides) were measured. Disease activity was assessed at baseline using the disease activity score 28 (DAS28) in 80 patients. For 40 RA patients, joint erosion score (JES) was established. The median JES was 14.1 with a standard deviation of 11.5. Anti-CarP antibodies were correlated with joint erosion score (ρ = 0.34, 95 % CI 0.03–0.59; p = 0.0332). No correlation between ACPA and joint erosion score was observed. No individual marker correlated with DAS28. When one ACPA peptide was combined with anti-CarP antibodies in a score (ACPA peptide 1 divided by anti-CarP), a statistically relevant correlation was found (p = 0.0264). In this small cohort, the presence of anti-CarP antibodies, but not ACPA correlate with joint erosion score. Anti-CarP antibodies combined with ACPA fine specificities correlated with DAS28. Therefore, anti-CarP antibodies might represent a promising marker to predict joint damage and disease activity in RA patients.
Similar content being viewed by others
Abbreviations
- ACPA:
-
Anti-citrullinated peptide antibodies
- AUC:
-
Area under the curve
- CCP:
-
Cyclic citrullinated peptide
- LR:
-
Likelihood ratio
- MCV:
-
Mutated citrullinated vimentin
- RF:
-
Rheumatoid factor
- VCP:
-
Viral citrullinated peptide
- ROC:
-
Receiver operating characteristic
- RU:
-
Relative units
- SARD:
-
Systemic autoimmune rheumatic disease
- SLE:
-
Systemic lupus erythematosus
- SSc:
-
Systemic sclerosis
References
van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7:391–8.
Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev. 2010;10:90–3.
Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273–81.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
Kessenbrock K, Raijmakers R, Fritzler MJ, Mahler M. Synthetic peptides: the future of patient management in systemic rheumatic diseases? Curr Med Chem. 2007;14:2831–8.
Levesque MC, Zhou Z, Moreland LW. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum. 2009;60:2211–5.
van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006;6:37–41.
Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12:318–22.
Willemze A, Bohringer S, Knevel R, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis. 2012;71:268–74.
Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108:17372–7.
Shi J, van de Stadt LA, Levarht EW, et al. Anti Carbamylated Protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65:911–5.
Shi J, Willemze A, Janssen GM, et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’ method. Ann Rheum Dis. 2013;72:148–50.
Shi J, van Veelen PA, Mahler M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13:225–30.
Jiang X, Trouw LA, van Wesemael TJ, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73:1761–8.
Kok MB, Tegelaers FP, van Dam B, van Rijn JL, van Pelt J. Carbamylation of albumin is a cause for discrepancies between albumin assays. Clin Chim Acta. 2014;434:6–10.
Scinocca M, Bell DA, Pope J, Cairns E, Barra L. Rheumatoid arthritis patients have anti-homocitrullinated fibrinogen antibodies. Arthritis Rheum. 2012;63:850.
Scinocca M, Bell DA, Racape M, et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol. 2014;41:270–9.
Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780–3.
van Riel PL, Schumacher HR Jr. How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol. 2001;15:67–76.
van der Heijde D, Kalden J, Scott D, Smolen J, Strand V. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis. 2004;63:737–9.
Silveira IG, Burlingame RW, von Muhlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol. 2007;26:1883–9.
Bossuyt X, Coenen D, Fieuws S, et al. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis. 2009;68:287–9.
Somers K, Geusens P, Elewaut D, et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun. 2011;36:33–46.
Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther. 2011;13:R13.
Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205227.
Conrad K, Roggenbuck D, Reinhold D, Dorner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev. 2010;9:431–5.
Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:R106.
Acknowledgments
We thank Brian McEvilly (Inova Diagnostics) for proof reading and valuable suggestions.
Conflict of interest
Maria Infantino, Francesca Meacci, Mariangela Manfredi, Maurizio Benucci none declared. Alvin Yee, Gabriella Lakos, Tyler Webb, Andrea Seaman and Michael Mahler are employed at Inova Diagnostics, Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yee, A., Webb, T., Seaman, A. et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 61, 24–30 (2015). https://doi.org/10.1007/s12026-014-8560-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-014-8560-x